Aeglea BioTherapeutics, which is developing enzymes for rare genetic metabolic diseases and tumors, announced terms for its IPO on Monday.
The Austin, TX-based company plans to raise $60 million by offering 3.5 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Aeglea BioTherapeutics would command a fully diluted market value of $203 million.
Aeglea BioTherapeutics was founded in 2013 and booked $6 million in grant revenue for the 12 months ended December 31, 2015. It plans to list on the Nasdaq under the symbol AGLE. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal. It is expected to price during the week of April 4, 2016 .
The article Metabolic biotech Aeglea BioTherapeutics sets terms for $60 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.